- Boston Scientific ( NYSE: BSX ) and Nevro ( NYSE: NVRO ) said they reached a settlement in their intellectual property litigations.
- Under the agreement, Boston Scientific will pay net $85M and the settlement concludes all existing litigations between BSX and NVRO, the two companies said in an Aug. 1 press release.
- Nevro said it will grant Boston Scientific a worldwide, non-exclusive, non-transferable license to practice paresthesia-free therapy at frequencies below 1,500 Hz and a covenant not to sue for any features in any current BSX products for frequencies below 1,500 Hz.
- In addition, Boston Scientific will grant Nevro a worldwide, non-exclusive, non-transferable license under BSX's patent families and a covenant not to sue for any features embodied in any current Nevro products.
For further details see:
Boston Scientific to pay $85M to Nevro as part of settlement to resolve patent litigation